/

CRVS

Corvus Pharmaceuticals, Inc.Closed

9.41−0.64 −6.37%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 9.41 0.00%

Open

9.99

Prev close

10.05

Day range

9.3210.03

52-week range

6.3926.95

Volume

1.69M1.75×

Mkt cap

791.58M

P/E ttm

—

Fwd P/E

-8.81

EPS ttm

-0.6200

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−65.08%

Price Chart

Yahoo Finance · delayed

CRVSOct 13, 2026O 9.99H 10.03L 9.32C 9.41−0.64 (−6.37%)Vol 1.69M

SMA 5013.08
SMA 20014.25

1Y change +35.79% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CRVS Corvus Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.89%
1 month: −27.11%
3 months: −37.14%
6 months: −38.30%
Year to date: +22.21%
1 year: +32.35%

Valuation & ownership

Market cap: 791.58M
Enterprise value: 577.08M
P/E (ttm): —
Forward P/E: -8.81
PEG ratio: —
Price / book: 3.51
Price / sales (ttm): —
EV / EBITDA: -10.15
EPS (ttm): -0.6200
EPS (forward): -1.07
Beta (5y monthly): 1.43
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 84.12M
Float: 72.62M
Short % of float: 24.05%
Short ratio (days): 15.44
Held by insiders: 3.51%
Held by institutions: 85.82%
Avg volume (3m): 964.02K
50-day average: 13.16
200-day average: 14.24
52-week change: +32.35%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 24.4
vs 50-day SMA: −28.07%
vs 200-day SMA: −33.95%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.17%
Realised vol (20d, ann.): 58.8%
From 52-week high: −65.08%
From 52-week low: +47.26%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.13 on a 1 (strong buy) – 5 (sell) scale

Mean target

33.14

+252.21% implied

Low 27.00Median 32.00High 42.00

Recommendation trend

Now8 / 0 / 0
1m ago8 / 0 / 0

DES

About Corvus Pharmaceuticals, Inc.

Yahoo Finance profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 37
Headquarters: South San Francisco, CA, United States
Website: corvuspharma.com
Officers

SEAS

Seasonality · CRVS

2016–2026 · monthly returns

Strongest month May +29.31%Weakest month Apr −7.40%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	168.8	-11.8	-19.9	3.8	-18.3	20.4	-11.2	5.9	-17.9	-18.3			+22.2%
2025	0.2	-24.6	-21.3	12.9	5.3	5.8	4.3	37.6	28.4	9.1	14.1	-16.0	+43.9%
2024	13.6	12.0	-20.5	-12.9	39.4	-15.7	41.2	74.3	17.9	67.4	2.8	-41.1	+204.0%
2023	-3.5	-11.0	24.7	18.7	181.5	-24.7	-1.7	-5.8	-31.1	-22.6	35.4	15.0	+107.1%
2022	-25.3	-1.7	-7.3	-20.1	-21.4	-3.9	-11.1	9.0	-14.6	5.9	7.5	-8.8	−64.7%
2021	4.5	-6.5	-11.5	-8.4	-2.8	-2.6	-21.7	8.1	114.2	-6.4	-24.7	-29.3	−32.3%
2020	1.5	-37.7	-38.7	15.2	42.0	-21.2	55.9	-10.6	5.8	-1.2	0.8	-10.8	−34.6%
2019	8.7	21.3	-16.9	5.2	-10.9	-0.8	4.5	-12.8	-11.7	10.6	-8.4	78.4	+48.2%
2018	-18.7	-2.7	40.8	-16.7	43.0	-20.0	-10.1	11.0	-21.7	-11.5	-21.2	-38.6	−64.6%
2017	-1.3	1.8	44.4	-52.2	2.3	19.1	1.1	32.2	-1.4	-14.8	-17.5	-7.6	−27.6%
2016				-15.6	14.8	1.5	-7.8	3.8	20.5	-18.8	15.6	-7.3	−1.4%

INSD

Insider Activity · CRVS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 10, 2026	Moore David ScottDirector	Purchase at price 11.53 per share.	21.7K	$250.24K
May 17, 2026	Miller Richard AChief Executive Officer	Purchase at price 12.01 - 12.05 per share.	6.9K	$83.45K
Jun 26, 2025	Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Sale at price 4.16 per share.	1.18M	$4.89M
Jun 26, 2025	Thompson Peter ADirector and Beneficial Owner of more than 10% of a Class of Security	Sale at price 4.16 per share.	1.18M	$4.89M
Jun 26, 2025	Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 3.50 per share.	1.40M	$4.89M
Jun 26, 2025	Thompson Peter ADirector and Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 3.50 per share.	1.40M	$4.89M
Jun 3, 2025	Jones William BentonOfficer	Conversion of Exercise of derivative security at price 3.50 per share.	19.4K	$67.75K
May 6, 2025	Miller Richard AChief Executive Officer	Conversion of Exercise of derivative security at price 3.50 per share.	559.1K	$1.96M

CRVS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CRVS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Corvus Pharmaceuticals, Inc.

Seasonality · CRVS

Insider Activity · CRVS

Congress Trades · CRVS

Investors Holding CRVS

Investors Holding CRVS

Congress Trades · CRVS

Insider Activity · CRVS

Seasonality · CRVS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Corvus Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News